HM15275
HM15275 has been studied in 1 paper since 2025: 1 trial in people. The newest paper, Jun 13, 2025: “Safety, Tolerability, and Pharmacokinetics of HM15275, a Novel GLP-1, GIP, and Glucagon Triple Receptor Agonist—Preliminary Results from a Phase 1 Study”.
1 paper studies it1 findingUpdated
“The highest dose cohort showed the greatest reduction, with a mean weight loss of -2.49 kg +- 2.32 and a -2.15% change.”
- 1 lab
- 1 trial, none about aging
- 1 of 1 trial sponsored by its developers
- Human trial1
What did studies of HM15275 find?
1Studies of HM15275 measured 1 outcome; the most studied are body weight (1 study).
Body weight
downin humans1
1 study
Body weight
downin humans1
HM15275 decreases body weight in humans (-2.49 kg +- 2.32 (-2.15%)).
“The highest dose cohort showed the greatest reduction, with a mean weight loss of -2.49 kg +- 2.32 and a -2.15% change.”
Human trialhighest dose cohort (B4, 0.5-4 mg) on Day 2929 daysn = 40
ADA Scientific Sessions 2025 abstract
Who is developing HM15275?
1 company: Hanmi Pharmaceutical Company.
- Companies
- Hanmi Pharmaceutical CompanyPhase 2type 2 diabetes
Trial sponsors
Company1 trialPhase 2180 people
Latest
ADA Scientific Sessions 2025 Abstract
Safety, Tolerability, and Pharmacokinetics of HM15275, a Novel GLP-1, GIP, and Glucagon Triple Receptor Agonist—Preliminary Results from a Phase 1 Study
Randomized trial in peopleInterventions